Buprenorphine transmucosal - BioDelivery Sciences International

Drug Profile

Buprenorphine transmucosal - BioDelivery Sciences International

Alternative Names: BELBUCA; BEMA Buprenorphine; BEMA® LA; BEMA® Long Acting; Buprenorphine buccal film; Buprenorphine long acting; EN 3409; Opioid analgesic transmucosal

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator BioDelivery Sciences International
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 15 May 2017 BioDelivery Science International expects approval of buprenorphine transmucosal in Canada in June 2017
  • 31 Mar 2017 BioDelivery Sciences receives patent extension for BEMA® drug delivery technology platform in USA
  • 09 Jan 2017 Transmucosal buprenorphine is no longer licensed to Endo Pharmaceuticals worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top